Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 209.2
(0.07%)
INR 209.2
(0.07%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 75.57 Million INR | 44.03% |
| 2022 | 52.47 Million INR | 0.0% |
| 2021 | - INR | 0.0% |
| 2020 | - INR | 0.0% |
| 2019 | - INR | 0.0% |
| 2018 | - INR | 0.0% |
| 2017 | - INR | 0.0% |
| 2016 | - INR | 0.0% |
| 2015 | - INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2013 | - INR | -100.0% |
| 2012 | 3.2 Million INR | 18.57% |
| 2011 | 2.7 Million INR | 2.7% |
| 2010 | 2.63 Million INR | -98.7% |
| 2009 | 202.79 Million INR | -27.49% |
| 2008 | 279.65 Million INR | -30.75% |
| 2007 | 403.81 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2024 Q2 | - INR | 0.0% |
| 2023 Q2 | 81.63 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 75.57 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 75.57 Million INR | 44.03% |
| 2022 FY | 52.47 Million INR | 0.0% |
| 2022 Q4 | 52.47 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | 0.0% |
| 2022 Q2 | 53.63 Million INR | 0.0% |
| 2021 Q1 | - INR | 0.0% |
| 2021 FY | - INR | 0.0% |
| 2021 Q4 | - INR | 0.0% |
| 2021 Q3 | - INR | 0.0% |
| 2021 Q2 | - INR | 0.0% |
| 2020 FY | - INR | 0.0% |
| 2020 Q3 | - INR | 0.0% |
| 2020 Q2 | - INR | 0.0% |
| 2020 Q4 | - INR | 0.0% |
| 2019 Q2 | - INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2019 Q3 | - INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| 2019 Q4 | - INR | 0.0% |
| 2018 FY | - INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2018 Q3 | - INR | 0.0% |
| 2018 Q2 | - INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | - INR | 0.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2016 Q3 | - INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2015 Q2 | - INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2015 Q3 | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2014 Q2 | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2014 Q4 | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 1.61 Million INR | 0.0% |
| 2013 Q4 | - INR | 0.0% |
| 2012 FY | 3.2 Million INR | 18.57% |
| 2012 Q4 | 3.2 Million INR | 0.0% |
| 2012 Q2 | 2.69 Million INR | 0.0% |
| 2011 Q4 | 2.7 Million INR | 0.0% |
| 2011 Q2 | - INR | 0.0% |
| 2011 FY | 2.7 Million INR | 2.7% |
| 2010 FY | 2.63 Million INR | -98.7% |
| 2009 FY | 202.79 Million INR | -27.49% |
| 2008 FY | 279.65 Million INR | -30.75% |
| 2007 FY | 403.81 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bal Pharma Limited | 363.82 Million INR | 79.229% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Alkem Laboratories Limited | 400 Million INR | 81.108% |
| Divi's Laboratories Limited | 20 Million INR | -277.85% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 95.018% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 48.804% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 95.882% |
| Mankind Pharma Limited | 248.67 Million INR | 69.611% |
| Medicamen Biotech Limited | 12.55 Million INR | -501.912% |
| Medico Remedies Limited | 8.67 Million INR | -771.425% |
| Megasoft Limited | 1.35 Billion INR | 94.431% |
| Procter & Gamble Health Limited | 68.8 Million INR | -9.84% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.696% |
| Sequent Scientific Limited | 1.42 Billion INR | 94.705% |
| Sigachi Industries Limited | 265.79 Million INR | 71.569% |
| Ajanta Pharma Limited | 235.2 Million INR | 67.87% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -468.195% |
| Brooks Laboratories Limited | 3.56 Million INR | -2019.776% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -18792.5% |
| Themis Medicare Limited | 267.74 Million INR | 71.775% |
| Unichem Laboratories Limited | 382.22 Million INR | 80.229% |
| Hester Biosciences Limited | 1.81 Billion INR | 95.843% |
| Venus Remedies Limited | 386.8 Million INR | 80.463% |
| Indoco Remedies Limited | 3.51 Billion INR | 97.851% |
| Ind-Swift Limited | 10.09 Billion INR | 99.251% |
| Aarti Drugs Limited | 2.75 Billion INR | 97.255% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -171.483% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 98.738% |
| Granules India Limited | 689.71 Million INR | 89.043% |
| Gufic Biosciences Limited | 1.53 Billion INR | 95.092% |
| Hikal Limited | 4.22 Billion INR | 98.213% |
| RPG Life Sciences Limited | -30.3 Million INR | 349.406% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 64.414% |
| Windlas Biotech Limited | 20.18 Million INR | -274.48% |
| ZIM Laboratories Limited | 356 Million INR | 78.773% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 32.301% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.761% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.646% |
| Bajaj HealthCare Limited | 650.34 Million INR | 88.38% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Ipca Laboratories Limited | 5.8 Billion INR | 98.698% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 99.122% |
| NATCO Pharma Limited | 53 Million INR | -42.585% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 94.614% |
| Shilpa Medicare Limited | 5.6 Billion INR | 98.651% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 92.859% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.529% |
| Wanbury Limited | 820 Million INR | 90.784% |
| Wockhardt Limited | 8.91 Billion INR | 99.152% |
| Strides Pharma Science Limited | 6.71 Billion INR | 98.875% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 78.768% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -441.022% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 87.982% |
| Eris Lifesciences Limited | 6.54 Billion INR | 98.845% |
| Lupin Limited | 1.55 Billion INR | 95.133% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 29.109% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 6299.344% |
| Valiant Laboratories Limited | 746.63 Million INR | 89.879% |
| Zydus Lifesciences Limited | 251 Million INR | 69.892% |
| FDC Limited | 2.46 Million INR | -2964.477% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 68.033% |
| Novartis India Limited | 50.7 Million INR | -49.053% |
| Neuland Laboratories Limited | 449.2 Million INR | 83.177% |
| Morepen Laboratories Limited | 33.64 Million INR | -124.643% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 43.411% |